1. Home
  2. MTNB vs LABT Comparison

MTNB vs LABT Comparison

Compare MTNB & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

HOLD

Current Price

$0.28

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$1.87

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MTNB
LABT
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
4.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
MTNB
LABT
Price
$0.28
$1.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
578.3K
253.1K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
59.84
N/A
EPS
N/A
N/A
Revenue
$119,750.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.66
52 Week High
$3.09
$4.72

Technical Indicators

Market Signals
Indicator
MTNB
LABT
Relative Strength Index (RSI) 27.44 26.54
Support Level N/A $1.88
Resistance Level $0.66 $2.92
Average True Range (ATR) 0.07 0.43
MACD -0.03 -0.09
Stochastic Oscillator 1.70 12.50

Price Performance

Historical Comparison
MTNB
LABT

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: